Periodic update on transaction details related to Philips� share repurchases

October 21, 2016

  • Link copied

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today reported the transaction details related to the repurchases of its own common shares made in the period from October 14, 2016 up to and including October 20, 2016. 


These repurchases were made under (i) the EUR 1.5 billion share repurchase program for capital reduction purposes and (ii) the repurchase program to cover long term incentive and employee share purchase plans. Further details can be found in the table below and via this link.


Total number of repurchased shares

Weighted average purchased price (EUR)

October 14, 2016



October 17, 2016



October 18, 2016



October 19, 2016



October 20, 2016



Philips has now completed the program referred to under (i) above, and will continue with the program referred under (ii) above.

  • Link copied

For further information, please contact:

Ben Zwirs

Philips Group Communications

Tel.: +31 6 15213446



Vanessa Bruinsma-Kleijkers

Philips Investor Relations

Tel.: +31 20 5977447


About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company, headquartered in the Netherlands, is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips’ health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at

You are about to visit a Philips global content page


Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.